Marché mondial des médicaments contre les crises néonatales – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché

En raison du manque de données probantes disponibles pour aider à décider de l’utilisation appropriée des médicaments pour les enfants de tous âges atteints de diverses formes d’épilepsie, les médecins sont confrontés à des problèmes particuliers lorsqu’ils traitent les enfants épileptiques. Cependant, des progrès ont récemment été réalisés dans la compréhension de la manière dont les médicaments antiépileptiques (MAE) peuvent être utilisés pour traiter les crises du nouveau-né et les spasmes infantiles, qui sont des troubles épileptiques qui surviennent au cours de la première année de vie. L’efficacité des MAE dans le traitement de ces maladies a été contestée et il est difficile de prédire le sort de ces problèmes pour chaque enfant. Toute avancée est donc la bienvenue.

Data Bridge Market Research analyse que le marché des médicaments contre les crises néonatales était évalué à 222,5 millions USD en 2021 et devrait atteindre 290,73 millions USD d'ici 2029, enregistrant un TCAC de 3,40 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe Data Bridge Market Research comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée du rapport et segmentation du marché

Définition du marché

Les crises convulsives chez les nouveau-nés sont des décharges électriques anormales dans le système nerveux central qui se manifestent généralement par une activité musculaire stéréotypée ou des anomalies autonomes. L'électroencéphalographie confirme le diagnostic et des tests supplémentaires sont recommandés pour en déterminer les causes. Le traitement est déterminé par la cause sous-jacente. Les crises convulsives touchent jusqu'à 1,4 % des nouveau-nés à terme et 20 % des prématurés. Les crises convulsives peuvent être le signe d'une affection néonatale importante qui doit être évaluée immédiatement. L'absence de myélinisation et la création insuffisante de dendrites et de synapses chez les nouveau-nés empêchent la généralisation de l'activité électrique, c'est pourquoi la plupart des crises néonatales sont focales.

Dynamique du marché des médicaments contre les crises néonatales

Conducteurs

• Prévalence croissante de l'hypoxie-ischémie

La prévalence croissante de l'hypoxie-ischémie devrait influencer la croissance du marché des médicaments contre les crises néonatales. La cause la plus fréquente des crises néonatales est l'hypoxie-ischémie, qui peut survenir avant, pendant ou après l'accouchement. Les crises de cette nature peuvent être graves et difficiles à traiter, mais elles disparaissent généralement après 3 à 4 jours. Les crises peuvent être moins graves lorsque l'hypoxie du nouveau-né est traitée par hypothermie thérapeutique (généralement par refroidissement du corps entier), bien qu'elles puissent réapparaître lors du réchauffement.

• Hausse de l'incidence des infections néonatales

L'incidence croissante des infections néonatales devrait stimuler le taux de croissance du marché au cours de la période de prévision 2022-2029. Les crises peuvent survenir à la suite d'infections néonatales, notamment la méningite et la septicémie ; dans ces cas, les crises sont généralement accompagnées d'autres symptômes et signes. Chez les nouveau-nés, les streptocoques du groupe B et les bactéries à Gram négatif sont les causes d'infection les plus courantes. Les crises peuvent également être causées par une encéphalite causée par le cytomégalovirus, le virus de l'herpès simplex, le virus de la rubéole, Treponema pallidum, Toxoplasma gondii ou le virus Zika.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the neonatal seizures drugs? market. Additionally, rising healthcare expenditure and changing lifestyle of people will result in the expansion of neonatal seizures drugs? market. Along with this, rising prevalence rate of chronic disease such as thyroid, diabetes, and kidney disease, and favourable reimbursement policies will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the neonatal seizures drugs? market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of neonatal seizures drugs during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the neonatal seizures drugs? market. Additionally, the side effects of neonatal seizures drugs? will act as market restrain and further impede the market's growth rate during the forecast period of 2022-2029.

This neonatal seizures drugs? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neonatal seizures drugs? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Seizures in new-borns are a common neurological emergency. In terms new-borns, the incidence has been reported to range from 1 to 5.5 per 1000 live births, with greater rates recorded in preterm infants. In the United States, the incidence is estimated to be between 80 and 120 instances per 100,000 new-borns per year.

Neonatal seizures drugs? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Neonatal Seizures Drugs Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations, resulting from multiple precautionary lockdowns and other limitations imposed by governments all over the world. The neonatal seizures drugs market was no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors were likely to have a negative impact on the neonatal seizures drugs market's revenue trajectory. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.

Global Neonatal Seizures Drugs Market Scope

The neonatal seizures drugs? market is segmented on the basis of type, drug, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Tonic Seizures
• Clonic and Myoclonic Seizures
• Non Paroxysmal Repetitive Behaviours

Drug

• Dilantin
• Phenobarbital
• Other

Dosage

• Injection
• Tablets
• Others

Route of Administration

• Oral
• Parenteral
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Neonatal Seizures Drugs Market Regional Analysis/Insights

The neonatal seizures drugs? market is analysed and market size insights and trends are provided by country, type, drug, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the neonatal seizures drugs? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the neonatal seizures drugs? market because of the rising level of investment on research and development activities in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel themarket's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region. Also, surging prevalence of kidney diseases, thyroid and liver disorders and the number of generic medications will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Neonatal Seizures Drugs Market Share Analysis

The neonatal seizures drugs? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neonatal seizures drugs? market.

Some of the major players operating in the neonatal seizures drugs? market are:

• Merck KGaA (Germany)
• Eisai Co., Ltd. (Japan)
• AstraZeneca (UK)
• Sanofi (France)
• Novartis AG (Switzerland)
• Abbott (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• WOCKHARDT (Mumbai)
• Novo Nordisk A/S (Denmark)
• Glenmark Pharmaceuticals Limited (India)
• Cipla Inc. (US)
• Bausch Health Companies Inc. (Canada)
• Otsuka America Pharmaceutical, Inc. (États-Unis)
• Johnson & Johnson Private Limited (États-Unis)
• Takeda Pharmaceutical Company Limited (Japon)
• Sumitomo Corporation (Japon)
• Biocon (Inde)  

SKU-56594